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The effect of long-term intake of different doses (20, 40, and 60mg/kg/day) of a Fraxinus excelsior L. seed extract (FESE) on
spontaneously hypertensive rats (SHR) was evaluated. Water was used as control and captopril (50mg/kg/day) was used as positive
control. Systolic blood pressure, body weight, and food and liquid intake were registered weekly in SHR. The antioxidant and
vascular relaxing properties of FESE were also studied in these animals. The development of hypertension was attenuated in the
groups treated with captopril or FESE. The antihypertensive effect was more accentuated in the captopril group than in the FESE
groups, and it was paradoxically more accentuated in the groups treated with 20mg/kg/day or 40mg/kg/day of FESE than in the
group treated with the highest dose of this extract. Body weight gain and food intake increased in the FESE groups. After removing
the corresponding antihypertensive treatment, the arterial blood pressure and the bodyweight of the FESE treated animals returned
to control values. In addition, FESE increased plasma antioxidant capacity and decreased plasma and liver malondialdehyde levels.
Moreover, acetylcholine relaxation improved in the aorta rings from the FESE treated rats.
1. Introduction
Arterial hypertension is one of the most common causes of
cardio- and cerebrovascular complications. Although many
effective chemically synthesized drugs exist for the treat-
ment of hypertension, there is a great deal of interest in
using natural plant extracts to attenuate the increased blood
pressure levels in hypertensive patients and to prevent the
cardiovascular disorders associated with this disease [1–3].
The beneficial properties of many plants have been
frequently attributed to the presence of phenolic compounds.
Among them, iridoids, a particularly widespread group
of monoterpenes, retain their chemical composition even
when exposed to stressful environments or after processing.
Therefore, iridoids may be considered more stable and more
bioavailable than other well-known phenolic compounds,
as flavonoids [4]. In addition, several biological properties
have been attributed to iridoids which have been recognized
as important components of medicine and healthy diet [5,
6]. Despite the many known biological properties of these
compounds, their effects on blood pressure have been poorly
investigated [7–9].
A Fraxinus excelsior L. seed extract (FESE) was obtained
via a patented process [10]. The analytical study of FESE
revealed that it was rich in nuzhenide and GI3, two phenolic
compounds belonging to the secoiridoid type [11]. FESE
lowered the incremental postprandial plasma glucose con-
centration in nondiabetic volunteers [11] and limited weight
gain and hyperglycemia in high-fat induced obese mice [12].
Recently, we have demonstrated the short-term antihyper-
tensive effect of this extract in spontaneously hypertensive
rats (SHR), a model for essential hypertension in humans.
FESE also showed diuretic and antioxidant properties that
could contribute to the decreased arterial blood pressure in
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the SHR [13]. In addition, the safety and tolerability of this
extract for consumption in healthy subjects have also been
demonstrated [14].
Hypertension is a chronic disease that needs chronic
treatment. According to this idea, the aim of this study
was to evaluate the effect of the long-term intake of FESE
on the development of hypertension of SHR. Weight gain
and food and liquid intake were evaluated in the animals
throughout the experimental period. We also investigate the
possible antioxidant properties of FESE by analysing plasma
and liver tissue samples from the different groups of rats.
Moreover, we carried out complementary trials in aorta ring
preparations obtained from these rats in order to investigate
the possible modification of endothelial function by this
extract.
2. Material and Methods
2.1. General Protocol in the Rats and Blood Pressure Measure-
ments. After being weaned at 3 weeks, 60 male SHR (Charles
River Laboratories Espan˜a S.A.) were caged in groups of
five rats at a temperature of 23∘C with 12 h light/dark cycles.
They were in turn randomly divided into six groups of 10
animals with ad libitum intake. During the experimental
period, the SHR of the established groups were fed on a food
standard diet for rats (A04 Panlab, Barcelona, Spain). The
rats drank different fluids from weaning until the 20th week
of life (treatment period) and received therefore different
treatments: tap water (negative control), FESE 20mg/kg/day,
FESE 40mg/kg/day, FESE 60mg/kg/day, or captopril (Sigma,
USA) 50mg/kg/day (positive control). The quantities of the
different products, to be daily administered during this
period of life, were selected according to the results obtained
whenwe established the short-term antihypertensive effect of
FESE in SHR [13]. From the 20th to the 24th week of life all
the animals were given tap water (follow-up period). Five 20-
week-old rats of each group were sacrificed by decapitation.
Blood and liver samples were collected in these animals. We
measured the antioxidant capacity of the plasma samples and
determined malondialdehyde (MDA) plasma levels. Liver
MDA concentration was also determined. Moreover, the
thoraxes of the sacrificed rats were opened and the aorta
was quickly extracted to evaluate the endothelial function
in accordance with the studies published by Furchgott in
1980 and in 1999 [15, 16]. All these experiments are described
below.
Systolic blood pressure (SBP) was measured weekly in
the rats from the 6th to 24th week of life, by the tail cuff
method [17]. Before the measurements, the rats were kept
at 38∘C for 10–15 minutes to make the pulsations of the tail
artery detectable. Arterial blood pressuremeasurements were
performed at the same time of day (between 9 a.m. and 13
p.m.) in order to avoid the influence of the circadian cycle,
and the values of SBPwere obtained by estimating the average
reading of five measurements. Moreover, the person who
measured the arterial blood pressure in the animals did not
know the drinking fluid that had been administered to each
group.
The body weight of the rats was recorded weekly up to
the 24th week of life. Daily intake of drinking fluids and freely
accessible feedwas also estimatedweekly in the SHR from the
different groups throughout the experimental period.
At the end of the experimental period, the 24-week-old
rats were sacrificed by decapitation.The same determinations
and procedures took place in these animals as for the
sacrificed 20-week-old rats.
All the above-mentioned experiments were performed
as authorized for scientific research (European Directive
86/609/CEE and Royal Decree 223/1988 of the Spanish
Ministry of Agriculture, Fisheries and Food).
2.2. Plasma and Tissue Preparations. The blood samples
were collected into tubes containing lithium heparin as
anticoagulant and centrifuged at 3500 g for 20min to obtain
the plasma. Livers were homogenized at 4∘C in a Potter with
phosphate buffered saline (PBS) (0.01M PBS, 0.15M NaCl,
pH 7.4). The homogenates were centrifuged at 5000 g for
15min at 4∘C and the supernatant was recovered.The plasma
and the supernatants of the centrifuged samples were kept
frozen at 80∘C until analysis. The liver protein content was
determined by the bicinchoninic acid assay (Pierce, Rockford,
Ill, USA), using bovine serum albumin as standard.
2.3. Plasma Antioxidant Capacity. We measured the antiox-
idant capacity of the plasma samples by using the oxygen
radical absorbance capacity (ORAC) assay, as previously
described in Manso et al. (2008) [18]. Briefly, the final assay
mixture contained fluorescein as oxidable substrate, 2,2󸀠-
Azobis(2-amidinopropane) dihydrochloride (AAPH) as oxy-
gen radical generator, and the antioxidant trolox either as
standard or plasma samples. Samples and standards were
dissolved in PBS (pH 7.4). A Polarstar Galaxy plate reader
with a 485-P excitation and a 520-P emission filter was
used. Black 96-well microplates were used. Fluorescence
measurement was carried out at 37∘C and was recorded
every minute for 80min. ORAC values were calculated and
expressed as 𝜇mol of trolox equivalent/mL of plasma.
2.4. Measurement of Malondialdehyde. Plasma and liver
MDA levels were measured by the thiobarbituric (TBA)
assay previously described also in Manso et al. (2008) [18].
Briefly, plasma and homogenates of tissues were mixed with
trichloroacetic acid, and the tubes were kept in ice for 20min.
Samples were centrifuged at 1500 g for 15min. before adding
TBA to the supernatant; then, the mixture was boiled at 97∘C
for 30min. Spectrophotometric measurements at 535 nm
were made at 20∘C. Plasma MDA values were expressed
as nmol MDA/mL and, for the different tissues, as nmol
MDA/mg tissue protein.
2.5. Experiments in Aorta Rings. The thoracic aorta was
carefully cleaned of fat and connective tissue and cut into
rings (approximately 4mm in length). The aorta rings were
mounted between two steel hooks in isolated tissue cham-
bers containing Krebs-Henseleit solution with the follow-
ing compositions (in mmol/L): NaCl, 118; KCl, 4.7; CaCl
2
,
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2.5; KH
2
PO
4
, 1.2; MgSO
4
, 1.2; NaHCO
3
, 25; and glucose, 10.0.
The medium was gassed with carbogen and kept at 37∘C. All
rings were allowed to equilibrate for 1 h at a resting tension of
2 g before adding drugs. Isometric tension was recorded by
using an isometric force displacement transducer connected
to an acquisition system (Protos 5, Panlab, Spain). After the
equilibration period, the ringswere first contracted by 80mM
KCl to assess their functionality, and when the contraction
had reached the steady state (about 15min) the preparations
were washed until the basal tension was recovered. Then
the vessels were exposed to methoxamine (10−5M), and
the presence of functional endothelium was assessed by
the ability of acetylcholine (ACh, 10−9 to 10−5M) to induce
relaxation. Relaxant responses to ACh were expressed as a
percentage of the precontraction induced by methoxamine.
2.6. Statistical Analysis. The results are expressed as mean
values ± SEM for 5–10 experiments and were analysed by a
one- or two-way analysis of variance (ANOVA), by using the
GraphPad Prism software. For the analysis, we considered,
on the one hand, the treatment period (from weaning until
the 20th week of life) and, on the other hand, the follow-up
period (from the 20th to the 24th week of life). Differences
between the groups were assessed by the Bonferroni test and
were considered to be significant when 𝑃 < 0.05.
3. Results
3.1. Arterial Blood Pressure. Development of hypertension
was attenuated in the SHR groups treated with captopril or
FESE. The antihypertensive effect was more accentuated in
the group treated with captopril, and it was quite similar
in all the FESE groups. Nevertheless, it was paradoxically
more accentuated in the groups treated with 20mg/kg/day
or 40mg/kg/day of FESE than in the group treated with
the highest dose of this extract (60mg/kg/day) (Figure 1).
In addition, food intake increased somewhat in the FESE
groups, and all the rats treated with this extract showed an
increase in body weight gain. On the contrary, the animals
treated with captopril showed less body weight than the rats
of the water group, even if the food intake in all these animals
was similar (Figure 2). The arterial blood pressure increased
in the treated SHR when the corresponding antihypertensive
treatment was removed. Nevertheless, at 24 weeks of life,
systolic blood pressure remained lower in the captopril
group than in the other groups. Body weight of the FESE
treated animals returned to control values along the follow-
up period. Liquid intake was variable in all animals along the
experimental period, but we could appreciate a clear increase
in this variable in the captopril treated rats (Figure 3).
3.2. Plasma Antioxidant Capacity. Plasma ORAC values in
the 20-week old rats that had been long-term treated with
20 or 40mg/kg/day FESE were significantly higher than
the corresponding values in the control group. When these
treatments were removed, plasma ORAC values returned to
control values, and during the follow-up period (from the
20th to the 24th week of life) no significant differences were
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Figure 1: Systolic blood pressure (SBP) of spontaneously hyper-
tensive rats. The animals drank different fluids from weaning
until the 20th week of life (treatment period = T, indicated by
a solid bar) and received therefore different daily treatments: tap
water, 20mg/kg/day Fraxinus excelsior L. seed extract (FESE),
40mg/kg/day FESE, 60mg/kg/day FESE, or 50mg/kg/day captopril.
All rats drank tapwater from the 20thweek of life until the 24thweek
of life (follow-up period = F, indicated by an open bar). Data are
mean values± SEM for 10 animals in T and for 5 animals in F. Similar
letters represent no statistical differences (𝑃 > 0.05). 𝑃 estimated by
two-way ANOVA.
observed between the plasma ORAC values of these groups
of rats and the corresponding values in the control rats that
received tap water along all the experimental period. Long-
term treatment with 50mg/kg/day captopril did not modify
plasmaORACvalues in the rats and the animals that had been
treatedwith this drug showed also similarORACvalues to the
control animals along the follow-up period (Figure 4).
3.3. Plasma and Liver Malondialdehyde Levels. Long-term
treatment with all the used doses of FESE and also 50mg/kg/
day captopril significantly lowered plasma MDA equivalents
in the SHR. Long-term treatment with 20mg/kg/day FESE
has the most accentuated effect, and when the corresponding
treatments were removed, only MDA values of the rats that
had been treated with this dose of the extract remained
significantly lower when compared with the control group.
In addition, long-term treatment with all the used doses of
FESE and also 50mg/kg/day captopril, significantly lowered
liver MDA equivalents in the SHRwhen compared to control
group. When the corresponding treatments were removed,
all treated groups showed similar values compared to control
group (Figure 5).
3.4. Aorta Vascular Relaxation. Acetylcholine relaxation
improved in the aorta rings from the rats that had been
treated with captopril or FESE. In particular, acetylcholine
relaxation improved in the aorta rings from the rats that
had been treated with captopril, but no significant differences
were observed between the relaxations caused by this agonist
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Figure 2: Food intake and body weight of spontaneously hypertensive rats. The animals drank different fluids from weaning until the 20th
week of life (treatment period = T, indicated by a solid bar) and received therefore different daily treatments: tap water, 20mg/kg/day Fraxinus
excelsior L. seed extract (FESE), 40mg/kg/day FESE, 60mg/kg/day FESE, or 50mg/kg/day captopril. All rats drank tap water from the 20th
week of life until the 24th week of life (follow-up period = F, indicated by an open bar). Data are mean values ± SEM for 10 animals in T and
for 5 animals in F. Similar letters represent no statistical differences (𝑃 > 0.05). 𝑃 estimated by two-way ANOVA.
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Figure 3: Liquid intake of spontaneously hypertensive rats.The ani-
mals drank different fluids from weaning until the 20th week of life
(treatment period = T, indicated by a solid bar) and received there-
fore different daily treatments: tap water, 20mg/kg/day Fraxinus
excelsior L. seed extract (FESE), 40mg/kg/day FESE, 60mg/kg/day
FESE, or 50mg/kg/day captopril. All rats drank tap water from the
20th week of life until the 24th week of life (follow-up period =
F, indicated by an open bar). Data are mean values ± SEM for 10
animals in T and for 5 animals in F. Similar letters represent no
statistical differences (𝑃 > 0.05). 𝑃 estimated by two-way ANOVA.
in these preparations and the corresponding relaxations in
aorta rings from the groups that had been treated with
40mg/kg/day or 60mg/kg/day of FESE. In fact, acetylcholine
relaxation improvedmore in the aorta rings from the rats that
had been treated with these doses of FESE than in the aorta
preparations obtained from the 20mg/kg/day FESE treated
animals (Figure 6).
After the follow-up period, acetylcholine relaxation was
also more marked in the aorta rings from the rats that had
been treated with captopril or FESE than in the aorta rings
from the rats that drank water along all the experimental
period. No differences were observed between the different
treated groups.
4. Discussion
In a previous study, we demonstrated the short-term anti-
hypertensive effect of FESE in SHR. Nevertheless, this study
clearly demonstrated that this extract can also control arte-
rial blood pressure in these animals when it is long-term
administered. SHR are considered nowadays one of the best
experimental models to evaluate antihypertensive functional
food ingredients [19]. The progression of hypertension in
these animals is in fact similar to that in humans [20]. Several
researchers, including our own research group, have reported
that, before arterial blood pressure stabilizes in SHR, there
is an initial period in the life of these animals in which
this variable clearly increases [21–23]. After this period, the
arterial blood pressure in the SHR remained constantly high.
An initial gradual increase in SBP was in fact observed in
the present study in the SHR of the control group, and
we also noted the stabilized arterial blood pressure period
in these animals. Both, FESE and captopril, attenuated the
development of hypertension in the SHR and also clearly
decreased their SBP in the period with stabilized arterial
blood pressure values. Nevertheless, the decreases in SBP
caused by all the used doses of FESE were always less
accentuated than the decrease of this variable caused by
50mg/kg/day captopril. In this context, it is important to
notice that our research group characterized this dose of
captopril as a very high dose, that caused the maximum
effect when it was short-term administered to the SHR [13].
Captopril is in fact a well-known antihypertensive drug with
clinical use in hypertensive patients and, as was expected,
during the experimental period, the lowest values of SBP
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Figure 4: Histograms of the oxygen radical absorbance capacity
(ORAC) of plasma samples (𝜇mol Trolox/mL plasma) from spon-
taneously hypertensive rats. The animals drank different fluids
from weaning until the 20th week of life (treatment period = T)
and received therefore different daily treatments: tap water,
20mg/kg/day Fraxinus excelsior L. seed extract (FESE), 40mg/kg/
day FESE, 60mg/kg/day FESE, or 50mg/kg/day captopril. All rats
drank tap water from the 20th week of life until the 24th week of life
(follow-up period = F). Data are mean values ± SEM for 10 animals
in T and for 5 animals in F. Similar letters represent no statistical
differences (𝑃 > 0.05). 𝑃 estimated by one-way ANOVA.
were observed in the group of rats treated with 50mg/kg/day
of this drug, but the antihypertensive effect of FESE was
also maintained and could be clearly observed in the SHR
stabilized arterial blood pressure period. The highest dose of
FESE (60mg/kg/day) caused even less effect than the other
doses of this extract (20mg/kg/day and 40mg/kg/day), but
neither in the short-term study with FESE, we obtained the
most pronounced antihypertensive effect with the highest
dose of this product [13]. Moreover, it is important to state
that this paradox also happened with different polyphenols
and polyphenol-rich compounds that we have evaluated in
SHR [24].
After removing FESE treatments, arterial blood pressure
rose gradually in the rats. In fact, from the 22nd week of life,
SBP values were very similar in the rats that had drunk the
solutions of FESE and those that had drunk water. Different
researchers have similarly described a gradual rise in SBP
when the intake of other antihypertensive food derived
products was stopped in SHR [22, 25, 26]. We also observed
an increase in the arterial blood pressure of the rats that had
been treatedwith captopril when this treatmentwas removed.
Nevertheless, the reversion was less noticeable, because this
drug is a potent antihypertensive agent, and the rats that
had drunk the solution of captopril had minor values of SBP
than the other groups also during the follow-up period. Kost
et al. (2000) [27] also reported a slight increase in arterial
blood pressure in SHR following the withdrawal of captopril
treatment.
SHR receiving captopril gained weight at a lower rate
than the other animals even if the SHR treated with this
drug did not show an increase in food intake. This finding
is in agreement with previous studies showing that blockade
of renin angiotensin system slows body weight gain in this
rat strain [28]. It is nevertheless important to state that
the SHR treated with FESE showed higher values of body
weight than the control rats and slightly higher values of
dry food intake. The mechanism implicated in this orex-
igenic effect of FESE is unknown and should be studied
in the future. Nevertheless, liquid consumption increased
markedly in the rats that drank the captopril solution, but
this is not surprising because it has been clearly demon-
strated that angiotensin converting enzyme inhibitors induce
thirst and increase water intake and urine output in rats
[29, 30].
Thepotential antioxidant therapy in hypertensive patients
has been extensively studied [31]. Many plants with antihy-
pertensive properties, that are having a marked impact on
the food sector, are rich in phenolic antioxidant compounds.
The relationship between natural phenol content in natural
products and health is nevertheless still controversial, and
there are problems to draw general conclusions regarding a
health effect common to all phenolic compounds, as their
structures are extremely diverse. In spite of these difficulties, it
is important to have in mind that the secoiridoids nuzhenide
and GI3 (in particular GI3), which are present in FESE, act as
antioxidants [32] and have proved to have preventive effects
on oxidative stress in rats [33]. Moreover, our research group
has already demonstrated that the acute administration of
FESE improves arterial blood pressure and the antioxidant
state in SHR [13].There exist a large number ofmethodologies
aimed at evaluating the antioxidant capacity of complex
mixtures [34]. ORAC type methodologies stand among the
most employed ones tomeasure the total antioxidant potency
of foods and nutritional supplements. In addition, MDA is
a biomarker that enabled us to estimate lipid peroxidation
in the rats. In this study, we have clearly demonstrated that
the administration of 20mg/kg/day or 40mg/kg/day of FESE,
the most effective antihypertensive doses of this extract,
significantly increased plasma ORAC values in the SHR and
significantly decreased plasma and liver MDA levels in these
animals. Captopril failed nevertheless to increase the total
antioxidant capacity of the SHR plasma samples, even if
this drug enhances the antioxidant capacity in hypertensive
patients [35] and has been postulated as a free radical
scavenger [36, 37]. Moreover, FESE caused a more marked
decrease in liver MDA than captopril in the SHR. The effects
of FESE on the ORAC andMDA values did not totally disap-
pear after removing the treatment. In particular, the plasma
MDA values of the 24-week-old rats that had been treated
with 20mg/kg/day FESE remain significantly lower than
those of the control rats of the same age. We should there-
fore assume that the antioxidant properties of FESE could
justify, at least in part, the antihypertensive effects of this
extract.
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Figure 5: Malondialdehyde (MDA) equivalents in plasma and liver samples from spontaneously hypertensive rats. The animals drank
different fluids from weaning until the 20th week of life (treatment period = T) and received therefore different daily treatments: tap water,
20mg/kg/day Fraxinus excelsior L. seed extract (FESE), 40mg/kg/day FESE, 60mg/kg/day FESE, or 50mg/kg/day captopril. All rats drank
tap water from the 20th week of life until the 24th week of life (follow-up period = F). Data are mean values ± SEM for 10 animals in T and
for 5 animals in F. Similar letters represent no statistical differences (𝑃 > 0.05). 𝑃 estimated by one-way ANOVA.
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In this study, we could also assume that FESE improves
endothelial function, since the relaxation to acetylcholine
increased in the aorta rings from the SHR that had been
treated with FESE as compared to the control group. The
improvement was dose-dependent and was still observed in
the aorta from the rats after the follow-up period. Neverthe-
less, the relaxation to acetylcholine increased always more in
the aorta from the captopril positive control group than in
the aorta from the FESE groups. These results suggest that
the effect on endothelial function could also justify in part
the antihypertensive effect of FESE.
In summary, long-term intake of FESE improves arterial
blood pressure, oxidative stress, and endothelial function in
SHR. The slight and maintained effect produced by FESE
in the SHR suggests that this extract could be used as a
functional food ingredient with potential therapeutic benefits
in the prevention and treatment of hypertension and other
associated disorders. Nevertheless, we are aware that before
International Journal of Hypertension 7
any clinical use of FESE, it would be necessary to carry out
clinical studies to demonstrate its long-term antihypertensive
efficiency in humans. Having inmind the results presented in
this study, the possible orexigenic effect of FESE should also
be studied in the future.
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